Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the presentation of two abstracts at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations will feature clinical results for oral and injectable ribupatide, a GLP-1/GIP receptor dual agonist, highlighting the potential of the ribupatide franchise to deliver potentially differentiated options for people living with obesity and overweight. Hengrui will present data from their Phase 2 clinical trial of oral ribupatide in adults living with obesity, and Kailera will present data from their Phase 1 bridging study of ribupatide injection, which supported the initiation of Kailera's ongoing global Phase 3 KaiNETIC clinical program.